Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

The Relationship between RTS,S Vaccine-Induced Antibodies, CD4+ T Cell Responses and Protection against Plasmodium falciparum Infection

(2013) Michael T. White et al.   PLoS One

A Phase 1b Randomized, Controlled, Double-Blinded Dosage-Escalation Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabe Healthy Adults 18 to 45 Years of Age

(2013) Alphonse Ouédraogo et al.   PLoS One

Randomized, placebo-controlled trial to assess the safety and immunogenicity of an adenovirus type 35-based circumsporozoite malaria vaccine in healthy adults

(2013) C Buddy Creech et al.   Human Vaccines & Immunotherapeutics

Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum

(2012) Frederic Clement et al.   MALARIA JOURNAL

A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants

(2012)   NEW ENGLAND JOURNAL OF MEDICINE

A Statistical Interaction between Circumsporozoite Protein-Specific T Cell and Antibody Responses and Risk of Clinical Malaria Episodes following Vaccination with RTS,S/AS01E

(2012) Francis M. Ndungu et al.   PLoS One

The RTS,S vaccine candidate for malaria

(2011) Jason A Regules et al.   Expert Review of Vaccines

Safety and efficacy of the RTS,S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial

(2011) Kwaku Poku Asante et al.   LANCET INFECTIOUS DISEASES

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial

(2011) Ally Olotu et al.   LANCET INFECTIOUS DISEASES

First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Protective Immunity Induced with the RTS,S/AS Vaccine Is Associated with IL-2 and TNF-α Producing Effector and Central Memory CD4+ T Cells

(2011) Joanne M. Lumsden et al.   PLoS One

Circumsporozoite-Specific T Cell Responses in Children Vaccinated with RTS,S/AS01E and Protection against P falciparum Clinical Malaria

(2011) Ally Olotu et al.   PLoS One

Further Analysis of Correlates of Protection from a Phase 2a Trial of the Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults

(2010) Ally Ibrahim Olotu et al.   JOURNAL OF INFECTIOUS DISEASES

Impact of national malaria control scale-up programmes in Africa: magnitude and attribution of effects

(2010) Richard W Steketee et al.   MALARIA JOURNAL

Heterologous prime–boost vaccination

(2009) Shan Lu   CURRENT OPINION IN IMMUNOLOGY

Heterologous prime–boost vaccinations for poverty-related diseases: advantages and future prospects

(2009) Katarina Radošević et al.   Expert Review of Vaccines

Long‐Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican Children

(2009) Jahit Sacarlal et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection

(2009) Kent E. Kester et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys

(2009) Ariane Rodríguez et al.   VACCINE

Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age

(2008) Philip Bejon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-γ and antibody responses in mice

(2008) Joseph P. Shott et al.   VACCINE